TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26681752
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (Atorvastatin)
Study: 24375159
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg three times daily for 2 months
Study: 24375159
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets/day) for 2 months
Study: 17042717
Drug: Clodronate 800
Normalized name: clodronic acid 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 800 mg daily
Study: 12059895
Drug: Propofol (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (Group P, bolus 1.5-2.0 mg/kg, maintenance 3.0-7.0 mg/kg/h) with remifentanil (10 microg/kg/h)
Study: 8562234
Drug: Metoprolol 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 6.25 mg twice daily
Study: 8562234
Drug: Celiprolol 25
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 25 mg daily
Study: 2896383
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g daily for 4 weeks)
Study: 668553
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg daily long-term)
Study: 31923768
Drug: Metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 25 mg and Aspirin 100 mg
Study: 23577699
Drug: Morphine-induced postconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-induced postconditioning (0.1 mg/kg)
Study: 20078390
Drug: MNC+G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNC+G-CSF
Study: 20078390
Drug: MNC-G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNC-G-CSF
Study: 10741625
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 2 g cefpirome
Study: 10741625
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 2 g cefpirome over 8 hours
Study: 10741625
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefpirome
Study: 10741625
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection and continuous infusion of cefpirome
Study: 8199795
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy from a clinical psychologist
Study: 2951093
Drug: Bread (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread (90 g)
Study: 2951093
Drug: Spaghetti (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaghetti (65 g)
Study: 2951093
Drug: Potatoes (285
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potatoes (285 g)
Study: 31752769
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy (PDT + anti-VEGF)
Study: 31752769
Drug: Deferred combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred combination therapy (PDT + anti-VEGF)
Study: 22949147
Drug: Aflibercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (4 mg/kg intravenously) plus FOLFIRI
Study: 26228675
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg/d)
Study: 8775611
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with dilute povidone-iodine solution after primary reclosure (Group A)
Study: 29202862
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy for Unusual Experiences (CBT-UED) plus routine care
Study: 19933408
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy in patients with Chagas disease
Study: 12100056
Drug: KLH-conjugated decapeptide
Normalized name: acetyl decapeptide-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Study: 12100056
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Study: 12100056
Drug: KLH-conjugated decapeptide
Normalized name: acetyl decapeptide-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly.
Study: 12100056
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intramuscularly.
Study: 9590465
Drug: Calcipotriene 30
Normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene 30 g per day (15 g ointment twice a day for 14 days)
Study: 7871091
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alpha-2 adrenoceptor antagonist
Study: 2832091
Drug: DAMP-ES (schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAMP-ES (schedule I: daily x5, doses of 10-90 mg/m2 per day)
Study: 2832091
Drug: DAMP-ES (schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAMP-ES (schedule II: 24-h continuous infusion, doses of 192 and 240 mg/m2)
Study: 2832091
Drug: Recommended starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recommended starting doses for phase II studies
Study: 12375799
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of taxanes and irinotecan
Study: 11853793
Drug: Chloramphenicol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (25 mg/kg 6 hourly)
Study: 11853793
Drug: Benzylpenicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin (50 mg/kg 6 hourly) plus Gentamicin (7.5 mg/kg daily)
Study: 26458124
Drug: Interferon beta‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b (250 μg or 500 μg)
Study: 21676368
Drug: Hydration plus
Normalized name: Biotrue Hydration Plus Multi-Purpose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration plus systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure
Study: 19407711
Drug: Desvenlafaxine (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/day)
Study: 19407711
Drug: Desvenlafaxine (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (flexible doses: 100-400 mg/day)
Study: 16940855
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg elemental zinc twice daily for 14 days)
Study: 16940855
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsule for 14 days)
Study: 8858666
Drug: BPIV-3 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPIV-3 vaccine
Study: 1518260
Drug: Postremission chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postremission chemotherapy (CT-MC)
Study: 6434387
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nisoldipine after acute administration
Study: 6434387
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nisoldipine at the end of three weeks of treatment (10 mg twice daily)
Study: 6434387
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg verapamil three times daily
Study: 31226936
Drug: Multimodal treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment: therapeutic workout program + medication review + diet adjustment + health education
Study: 31226936
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: medication review + diet adjustment + health education (regular workout recommendations)
Study: 29795561
Drug: rhTM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTM treatment
Study: 25226757
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program (protocol-defined pharmacist care)
Study: 19780875
Drug: Adefovir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir monotherapy (ADV)
Study: 15591724
Drug: Modified mastectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified mastectomy with adjuvant chemo- or radiation therapy
Study: 8041896
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment for glottic laryngeal cancer
Study: 8041896
Drug: Treatment recommendations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment recommendations for patients vs self
Study: 3276390
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of chemotherapy according to a modified Rosen schedule
Study: 3276390
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of chemotherapy followed by lung irradiation
Study: 26680684
Drug: Methazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (250 mg)
Study: 26680684
Drug: Aminophylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (400 mg)
Study: 26680684
Drug: Methazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (250 mg) with Aminophylline (400 mg)
Study: 24291456
Drug: Thrice-weekly structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly structured aerobic and resistance exercise intervention
Study: 11772295
Drug: Therapies aimed
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies aimed at eradicating chronic infections
Study: 7880675
Drug: Midline approach
Normalized name: amidoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midline approach with flexed lateral position (ML)
Study: 1099032
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with pH of 6
Study: 31488402
Drug: Nebulised hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised hypertonic saline (HS) treatment (4 mL of 3% sodium chloride every 6 hours)
Study: 25534727
Drug: LFF571 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LFF571 (200 mg four times daily for 10 days)
Study: 1322075
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg four times daily for 10 days)
Study: 23587029
Drug: Baseline HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HDL < 1.21 mmol/l
Study: 21440948
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin and gemfibrozil
Study: 20186637
Drug: Forgiveness intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Forgiveness intervention (10 weekly interpersonal forgiveness therapy sessions)
Study: 20186637
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (10 weekly sessions)
Study: 7908357
Drug: c7E3 bolus/c7E3
Approvals — FDA: no, EMA: no, PMDA: no
Description: c7E3 bolus/c7E3 infusion
Study: 7908357
Drug: c7E3 bolus/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: c7E3 bolus/placebo infusion
Study: 3047338
Drug: Vincristine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (1 mg/m2) and prednisone (0.6 mg/kg/d for seven days at 8-week intervals)
Study: 26936139
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high molecular weight (HMW) β‐glucan/d
Study: 26936139
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g low molecular weight (LMW) β‐glucan/d
Study: 26936139
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g low molecular weight (LMW) β‐glucan/d
Study: 22985900
Drug: Topical analgesic
Normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesic patches
Study: 22985900
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug patches (control)
Study: 22985900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medial and lateral prefrontal functional connections
Study: 18025650
Drug: Topical antiglaucoma
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiglaucoma agents
Study: 10687264
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (amoxicillin at 500 mg twice a day for 14 days, metronidazole at 500 mg twice a day for 10 days, omeprazole at 20 mg twice a day for 20 days)
Study: 30070398
Drug: Imagery Rehearsal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery Rehearsal Therapy + Cognitive Behavioral Therapy (IRT + CBT)
Study: 26991889
Drug: Exercise augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise augmentation of treatment as usual (part of STRIDE trial)
Study: 26991889
Drug: Cocaine plus
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine plus other stimulant use disorders
Study: 20799973
Drug: Multifaceted community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted community-based care program including facilitated bone mineral density testing, patient education, and patient-specific recommendations for osteoporosis treatment.
Study: 7573781
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of ethanol (0.5 g/kg)
Study: 2333581
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with vincristine, daunorubicin, prednisone, cytosine arabinoside, and 6-thioguanine; followed by consolidation treatment with VM-26, cyclophosphamide, BCNU, and L-asparaginase; CNS prophylaxis with intrathecal methotrexate.
Study: 2333581
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy for remaining patients.
Study: 2333581
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment including chemotherapy and BMT.
Study: 17557044
Drug: Endoscopic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapies (endoscopic mucosal resection, ablative therapies)
Study: 17557044
Drug: Mainstays of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainstays of treatment for advanced cancers (debulking surgery, chemotherapy, radiotherapy, palliative care)
Study: 8196849
Drug: Naproxen 1000
Normalized name: naproxen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1000 mg/day
Study: 11253158
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg/day, 400 mg/day)
Study: 9167210
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion at 30 ng/kg/min for 48 hours
Study: 23071528
Drug: Sirolimus (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (1.3 to 1.5 mg per day for a median of 19 months)
Study: 14968218
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg thrice daily for 5 days
Study: 14968218
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg thrice daily for 5 days followed by alpha-tocopherol 200 mg thrice daily for another 5 days
Study: 4003099
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Org 3770
Study: 4003099
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Org 3770
Study: 4003099
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Org 3770
Study: 30606225
Drug: Chiropractic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic manipulative therapy (CMT) - four treatments over a 2-week period
Study: 30606225
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control - no treatment during the 2-week period
Study: 24867903
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy and exercise program
Study: 22835512
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of systemic antihypertensives
Study: 17555427
Drug: Mitemcinal 10
Normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitemcinal 10 mg
Study: 15702239
Drug: Shoyu polysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoyu polysaccharides (SPS) 600 mg daily
Study: 9395621
Drug: HP-200 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-200 (7.5 g sachet mixed with water, orally)
Study: 1715501
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (4 IU/m2 per day) for 6 months
Study: 14624765
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 6 months
Study: 6857511
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (RL, 130 mEq sodium/L, 274 mOsm/L)
Study: 6857511
Drug: Hypertonic balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic balanced salt solution (HSL, 250 mEq sodium/L, 514 mOsm/L)
Study: 25669236
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive behavioral therapy (SCBT)
Study: 24121692
Drug: Water-based gel
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based gel applied during speculum examination
Study: 15878927
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (600 microg followed by 400 microg every 3 hours)
Study: 9620907
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy alone (n = 71)
Study: 9620907
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy in combination with anabolic steroid treatment (n = 67)
Study: 23490255
Drug: Multivitamins (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins (folic acid 0.8 mg, vitamin B6 10 mg, and vitamin B12 500 μg)
Study: 22333695
Drug: Thimerosal-free trivalent
Normalized name: Thimerosal
DrugBank: Thimerosal (DB11590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thimerosal-free trivalent inactivated influenza vaccine
Study: 22333695
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (US-licensed influenza vaccine)
Study: 9420639
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg coenzyme Q10 (CoQ10)
Study: 2261301
Drug: Delayed excretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed excretion greater than 10 min
Study: 2261301
Drug: No delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: No delayed excretion
Study: 7396058
Drug: Amoxicillin (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (375 mg, 3 times a day for 5 days)
Study: 30901380
Drug: PF‐00547659 (anti-MAdCAM-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00547659 (anti-MAdCAM-1 monoclonal antibody)
Study: 21302687
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray 10%
Study: 21302687
Drug: Tetracaine 2%
Normalized name: BENZOCAINE 14%/BUTAMBEN 2%/TETRACAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 2% solution
Study: 18457617
Drug: Intensive preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive preventive program (quarterly examinations by general practitioner, treatment adjustments, lifestyle reinforcement)
Study: 12437643
Drug: Normal HGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal HGF values (< 1.7 ng/ml, n = 69)
Study: 12437643
Drug: Elevated HGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated HGF (≥ 1.7 ng/ml, n = 26)
Study: 10599590
Drug: Biniwas (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biniwas (2 x 550 mg/day) for six months
Study: 7861247
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg every 4 months; 30 mg for infants 6-11 months)
Study: 6178567
Drug: Methisoprinol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methisoprinol (4 g/day per os in 4 divided doses for 2 weeks)
Study: 30448878
Drug: Dark roast
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark roast coffee blend (500 ml per day)
Study: 30448878
Drug: Water (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (500 ml per day)
Study: 22975068
Drug: Ghrelin synthesis
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin synthesis administration
Study: 22975068
Drug: Ghrelin replacement
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin replacement therapy during chemotherapy